Investigation Of Quality Of Life After Hormonal Treatment For Advanced Prostate Cancer

Objectives:Using EORTC QLQ-C30 and EORTC QLQ-PR25 measurement, evaluate quality of life effects of hormonal therapy for advanced prostate cancer. In a cross-sectional setting, to compare the Health-related quality of life of advanced prostate cancer with intermittent hormonal therapy and continual hormonal therapy to provide some evidence and support for future clinical decision making .Here we report on QOL outcome.Material and methods:A total of 53 outpatients and inpatients newly diagnosed with advanced prostate cancer from urology department in second hospital of Tianjin medical university through 2006 to 2008 , which acted as treatment team after initial hormonal therapy. and participated in the study. During this time, a total of 45 senior age-matched people (55y-80y) from Tianjin downtown zone entered in control arm. Using the questionnaire translated from EORTC QLQ-C30 V3.0 and EORTC QLQ-PR25 measurement, patients were administrated to complete investigation after 3,6 or 9 months' treatment and control people complete questionnaire at any time. Patients received 3 to 6 months LHRH agonists +Flutamide or Bicalutamide depending on their response. Patients with a good or moderate response were randomized to continuous or intermittent treatment. In the intermittent arm, treatment was stopped and restarted depending on PSA and/or clinical criteria. Import clinical information supplied by Excel and EpiData3.0, after Data collection, compare patients between intermittent hormonal therapy and continual hormonal therapy ,androgen depreviation treatment and control arm and then surgical castration and nonsurgical castration .Statistical analysis the Student t-test and nonparamete Wilcoxon was used.α=0.05.Results:Completion rate of questionnaires was 76.3%. Scores on 1 out of the 5 domains of the EORTC QLQ C30, physical function, were significantly better in the group receiving intermittent treatment (p <0.05). Scores on Global health status , role function , social function were equal between the groups. In addition. ADT has lower score comparing control arm except for physical and role function. Remarkably, treatment-related symptom appeared increased in continual group.Conclusions:After 2- year follow up, intermittent hormonal therapy for advanced prostate cancer by LHRH agonists has advantages in important QOL domains. Treatment-related scores appeared increased in the continual group. All these reasons for this study are not apparent and deserve further studies.